Literature DB >> 32603232

Deciphering Alzheimer's disease: predicting new therapeutic strategies via improved understanding of biology and pathogenesis.

Rita Khoury1, George T Grossberg2.   

Abstract

INTRODUCTION: There is no cure for Alzheimer's disease (AD). One explanation may pertain to the need to intervene as early as possible upstream from the accumulation of β-amyloid plaques and tau tangles. AREAS COVERED: A PUBMED literature search was completed to review the biological or pathological changes at the basis of disease initiation; this includes neuroinflammation, oxidative stress, microbiome changes and glymphatic system dysfunction. Innovative therapeutic strategies based on these mechanisms are also discussed. EXPERT OPINION: Improved understanding of the pathophysiological mechanisms that underly AD would assist in the identification of drug targets for clinical trials. Furthermore, pharmacokinetic and pharmacodynamic studies are key for the characterization of the properties of disease-modifying drugs and the improvement of their penetration of the blood-brain barrier. Drug targets can be examined at different stages of the disease, hence the importance of selecting and recruiting the appropriate participants, preferably at the earliest stage of AD. New trial designs should be established which primarily involve combination therapies that can work synergistically on common pathways. Going forward, innovative treatment strategies involving nanotechnology, young blood products transfusion and photobiomodulation also offer promise for the future.

Entities:  

Keywords:  Alzheimer’s disease; disease-modifying therapies; early intervention; pathophysiology

Mesh:

Substances:

Year:  2020        PMID: 32603232     DOI: 10.1080/14728222.2020.1790530

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  4 in total

1.  Uncharacterized RNAs in Plasma of Alzheimer's Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power.

Authors:  Cristina Barbagallo; Maria Teresa Di Martino; Margherita Grasso; Maria Grazia Salluzzo; Francesca Scionti; Filomena Irene Ilaria Cosentino; Giuseppe Caruso; Davide Barbagallo; Cinzia Di Pietro; Raffaele Ferri; Filippo Caraci; Michele Purrello; Marco Ragusa
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

Review 2.  Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer's Disease.

Authors:  Ankit Jana; Arkadyuti Bhattacharjee; Sabya Sachi Das; Niraj Kumar Jha; Avani Srivastava; Akshpita Choudhury; Rahul Bhattacharjee; Swagata De; Asma Perveen; Danish Iqbal; Piyush Kumar Gupta; Saurabh Kumar Jha; Shreesh Ojha; Sandeep Kumar Singh; Janne Ruokolainen; Kavindra Kumar Kesari; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2022-03-26       Impact factor: 5.682

Review 3.  microRNA-Based Biomarkers in Alzheimer's Disease (AD).

Authors:  Yuhai Zhao; Vivian Jaber; Peter N Alexandrov; Andrea Vergallo; Simone Lista; Harald Hampel; Walter J Lukiw
Journal:  Front Neurosci       Date:  2020-10-30       Impact factor: 4.677

4.  Microglial Heterogeneity and Its Potential Role in Driving Phenotypic Diversity of Alzheimer's Disease.

Authors:  Stefano Sorrentino; Roberto Ascari; Emanuela Maderna; Marcella Catania; Bernardino Ghetti; Fabrizio Tagliavini; Giorgio Giaccone; Giuseppe Di Fede
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.